JAK Janus Kinase

Cat.No.	Name	Information
M3030	S-Ruxolitinib	S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M1820	Tofacitinib	Tofacitinib (formerly tasocitinib, CP-690550) is a novel Janus Kinase 3 (JAK-3) kinase inhibitor with an IC50 value estimated at 0.2 μM.
M1660	AZ 960	AZ 960 is a novel and specific inhibitor of the JAK2 kinase with a Ki of 0.45nM in vitro.
M1646	AG490	AG490 (Tyrphostin AG490) is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively).
M1733	TG101348	TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM.
M1787	INCB18424	Ruxolitinib (INCB018424) is a first-in-class, potent, selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM. It is more than 130-fold more selective for JAK1, JAK2, and JAK3 than JAK3. It can be used in studies related to pemphigus, myelofibrosis and vitiligo.
M5944	Ruxolitinib phosphate	Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M3616	Tofacitinib citrate	Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
M2346	Filgotinib	Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively.
M2044	AZD1480	AZD1480 is a novel small-molecule inhibitor of JAK1/2 with IC50 of 1.3 nM and 0.26 nM, respectively.
M49626	TK4g	TK4g is a Janus kinase (JAK) inhibitor with the IC50 values of 12.61 nM and 15.80 nM for JAK2 and JAK3, respectively.
M49625	TK4b	TK4b is a Janus kinase (JAK) inhibitor with the IC50 values of 19.40 nM and 18.42 nM for JAK2 and JAK3, respectively.
M49624	Thi-DPPY	Thi-DPPY is a potent and orally active JAK3 inhibitor with IC50 values of 62.4, 1.38 nM for BTK, JAK, respectively.
M49623	Ten01	Ten01 has 5.0 nM activity against JAK1 kinase.
M49622	SD-1008	SD-1008 is a potent JAK inhibitor.
M49621	Rovadicitinib hydrochloride	Rovadicitinib hydrochloride is a JAK inhibitor with an IC50 value <20 nM.
M49620	Rovadicitinib	Rovadicitinib is a Janus kinase (JAK) inhibitor with an IC50 value <20 nM.
M49619	QL-1200186	QL-1200186 is anorally activeand selective inhibitor ofTYK2.
M49618	Peficitinib hydrochloride	Peficitinib (ASP015K) hydrochloride is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.
M49617	Peficitinib hydrobromide	Peficitinib (ASP015K) hydrobromide is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.
M49616	Pacritinib citrate	Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM).
M49614	Nimucitinib	Nimucitinib is a Janus kinase (JAK) inhibitor.
M49613	Momelotinib Mesylate	Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.
M49612	MMT3-72-M2	MMT3-72-M2 is an MMT3-72 metabolite.
M49611	MMT3-72	MMT3-72 is a weak inhibitor of JAK1.
M49610	JAK-IN-5	JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.
M49609	JAK-IN-4	JAK-IN-4 is a proagent of a JAK inhibitor, effective in murine collagen induced arthritis model.
M49608	JAK-IN-35	JAK-IN-35 is a JAK2 inhibitor that canb be used in cancer research.
M49607	JAK-IN-34	JAK-IN-34 is a potent against of JAKs with IC50 values of 0.40, 0.83, 2.10, 1.95 nM target JAK1, JAK2, JAK3, TYK2, respectively.
M49606	JAK-IN-33	JAK-IN-33 is a JAK inhibitor.

By Signaling Pathways

By Product Type

Signaling Pathways

JAK Janus Kinase

Get to Know Us

Customer Support

Resources

Contact Us